{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-089301","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.199083+00:00","generated_at":"2026-05-31T13:45:55.709759+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adaptive Biotechnologies Q2 MRD revenue up 36% YoY; updates FY guidance","bullets":["Total Q2 revenue $43.2M (-12% YoY); MRD revenue $35.3M (+36%), Immune Medicine $7.9M (-66%).","Net loss $46.2M vs $47.8M YoY; Adjusted EBITDA loss $21.4M vs $24.8M.","clonoSEQ test volume 18,520 (+36% YoY); recognized $3.0M MRD regulatory milestone.","FY 2024 MRD revenue guidance raised to $140-145M (from $135-140M); total OPEX guidance lowered to $340-350M.","Cash and securities $291.9M as of June 30."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-089301","json":"https://secwatch.observer/filing/0000950170-24-089301.json","markdown":"https://secwatch.observer/filing/0000950170-24-089301.md","text":"https://secwatch.observer/filing/0000950170-24-089301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024089301/0000950170-24-089301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024089301/adpt-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:45:55.709759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}